PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial
URL https://www.nature.com/articles/s41591-024-02979-8.pdf Stage Normal Science Paradigm framing The dominant paradigm is the application of Chimeric Antigen Receptor (CAR) T cells for cancer treatment, specifically within the sub-paradigm of its use for solid tumors, exemplified by metastatic castration-resistant prostate cancer (mCRPC). Highlights This Phase 1 clinical trial investigates PSCA-CAR T cell therapy for mCRPC, falling squarely